Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 2

Status

Terminated 3Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Sarcoma 1Dermatologic 1

Conditions

Neuroblastoma 2Glioblastoma 2Medulloblastoma 1Gliosarcoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × TPI-287 × CNS × Clear all
NCT01483820 2024-08-06

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Milton S. Hershey Medical Center

Phase 1/2 Terminated
8 enrolled 9 charts
CNS

Medulloblastoma, Neuroblastoma

NCT01505608 2024-08-06

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Milton S. Hershey Medical Center

Phase 1/2 Terminated
14 enrolled 11 charts
CNS

Neuroblastoma

NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Cortice Biosciences, Inc.

Phase 1/2 Suspended
92 enrolled
CNS

Glioblastoma

NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡